EAN 2026: Meta-analysis finds no added benefit of Radicava/Rilutek combo in ALS

A review of five studies has found no added benefit of using Daiichi Sankyo’s Radicava and Sanofi’s Rilutek as a combo in ALS. A review from five studies has found no added benefit of using Daiichi Sankyo’s Radicava (edaravone) and Sanofi’s Rilutek (riluzole) as a combo in ALS. The analysis included five studies comprising 548 patients, of whom 39.4% received combination therapy. Credit: Faizal Ramli / Shutterstock.com A systematic review and meta-analysis evaluating whether using Daiichi Sankyo’s Radicava (edaravone) and Sanofi’s Rilutek (riluzole) in combination provides additional clinical benefit compared with Rilutek alone in patients with amyotrophic lateral sclerosis (ALS)…

Source: Clinical Trials Arena